Caissa Capital Management ltd., 10% Owner at Avalo Therapeutics, Inc. (AVTX), bought 8,160 shares at $3.68 ($32K) on 2023-06-15, disclosed to the SEC on 2023-06-20.
Open-market purchase of $32k AVTX by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.68 | 3,160 | $12K | 36.8% |
| 2 | $3.90 | 3,000 | $12K | 37.0% |
| 3 | $4.14 | 2,000 | $8K | 26.2% |
| Total | $3.87 avg | 8,160 | $32K | 100% |
| Filing → |
| AVTX | BUY | 2023-06-09 | $56K | — | Filing → |
| AVTX | BUY | 2023-06-02 | $2K | — | Filing → |
| AVTX | BUY | 2023-05-30 | $7K | — | Filing → |